Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.

@article{Reynaud2015EfficacyAS,
  title={Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.},
  author={Quitterie Reynaud and Isabelle Durieu and Marine Dutertre and Stanislas Ledochowski and St{\'e}phane Durupt and Anne-Sophie Michallet and Denis Vital-Durand and J C Lega},
  journal={Autoimmunity reviews},
  year={2015},
  volume={14 4},
  pages={304-13}
}
OBJECTIVE This study aims to evaluate the response to rituximab (RTX) treatment in auto-immune hemolytic anemia (AIHA) patients. METHODS Studies were selected from MEDLINE up to March 2014. Two investigators independently extracted data on study design, patient characteristics, clinical features (AIHA type, disease duration, previous treatments), dose-schedule of rituximab, duration of treatment follow-up, and toxicities. Pooled overall response rate (ORR) and complete response (CR) rates… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…